A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy

Highlights • Tocilizumab is used as a biologic drug for rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman's disease. • IL-6 blockade strategy will be widely applicable for various refractory inflammatory autoimmune diseases. • The mystery remains as to why IL-6 is persistently...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Seminars in immunology 2014-02, Vol.26 (1), p.88-96
Hauptverfasser:	Tanaka, Toshio, Narazaki, Masashi, Ogata, Atsushi, Kishimoto, Tadamitsu
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute-Phase Proteins - biosynthesis Allergy and Immunology Animals Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Autoimmune Diseases - drug therapy Autoimmune Diseases - genetics Autoimmune Diseases - immunology Autoimmune Diseases - metabolism Autoimmunity Gene Expression Regulation - drug effects Humans IL-6 Immunomodulation - drug effects Inflammation Inflammation - drug therapy Inflammation - genetics Inflammation - immunology Inflammation - metabolism Interleukin-6 - genetics Interleukin-6 - metabolism Receptors, Interleukin-6 - antagonists & inhibitors Receptors, Interleukin-6 - metabolism RNA Processing, Post-Transcriptional Signal Transduction - drug effects Tocilizumab Transcription, Genetic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Tocilizumab is used as a biologic drug for rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman's disease. • IL-6 blockade strategy will be widely applicable for various refractory inflammatory autoimmune diseases. • The mystery remains as to why IL-6 is persistently expressed in various diseases.
ISSN:	1044-5323 1096-3618
DOI:	10.1016/j.smim.2014.01.009